

Supplemental information

Table S1: FDA-approved complement-targeted therapeutics as of March 2025

Disease indication	Drug	Target	Type (administration)
Paroxysmal nocturnal haemoglobinuria (PNH)	Eculizumab	C5	mAb (IV)
	Ravulizumab ¹	C5	mAb (IV)
	Bkemb ²	C5	mAb (IV)
	Pegcetacoplan	C3	small-molecule (SC)
	Iptacopan	Factor B	small-molecule (PO)
	Danicopan ³	Factor D	small-molecule (PO)
Atypical haemolytic syndrome (aHUS)	Eculizumab	C5	mAb (IV)
	Ravulizumab ¹	C5	mAb (IV)
	Bkemb ²	C5	mAb (IV)
Neuromyelitis optica spectrum disorder (NMOSD)	Eculizumab	C5	mAb (IV)
	Ravulizumab ¹	C5	mAb (IV)
Generalised myasthenia gravis (gMG)	Eculizumab	C5	mAb (IV)
	Ravulizumab ¹	C5	mAb (IV)
	Zilucoplan	C5	small-molecule (SC)
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)	Avacopan	C5aR	small-molecule (PO)
Cold agglutinins disease (CAD)	Sutimlimab	C1s	mAb (IV)
Coronavirus disease 2019 (COVID-19)	Vilobelimab ⁴	C5a	mAb (IV)
Geographic atrophy (GA) due to age-related macular degeneration (AMD)	Pegcetacoplan	C3	small-molecule (IVI)
	Avacincaptad	C5	RNA aptamer (IVI)
CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) disease.	Pozelimab	C5	mAb (IV)
IgA Nephropathy (IgAN)	Iptacopan	Factor B	small-molecule (PO)
C3 Glomerulopathy (C3G)	Iptacopan	Factor B	small-molecule (PO)

IV, intravenous; IVI, intravitreal; mAb, monoclonal antibody; PO, oral; SC, Subcutaneous.

¹ Ravulizumab differs from eculizumab by the substitution of four amino acids, which modifies its pharmacokinetics and pharmacodynamics, extending its half-life to four times that of eculizumab.

² Bkemb is an interchangeable biosimilar for Eculizumab.

³ Danicopan is FDA-approved as an add-on therapy to a C5 inhibitor specifically for treatment-experienced patients with clinically significant extravascular hemolysis.

1 ⁴ Vilobelimab received Emergency Use Authorization by the FDA for treating COVID-19 in
2 hospitalized adults when started within 48 hours of invasive mechanical ventilation or
3 extracorporeal membrane oxygenation.